Ming-Yue Fei, Yong Wang, Bin-He Chang, Kai Xue, Fangyi Dong, Dan Huang, Xi-Ya Li, Zi-Juan Li, Cheng-Long Hu, Ping Liu, Ji-Chuan Wu, Peng-Cheng Yu, Ming-Hua Hong, Shu-Bei Chen, Chun-Hui Xu, Bing-Yi Chen, Yi-Lun Jiang, Na Liu, Chong Zhao, Jia-Cheng Jin, Dan Hou, Xin-Chi Chen, Yi-Yi Ren, Chu-Han Deng, Jia-Ying Zhang, Li-Juan Zong, Rou-Jia Wang, Fei-Fei Gao, Hui Liu, Qun-Ling Zhang, Ling-Yun Wu, Jinsong Yan, Shuhong Shen, Chun-Kang Chang, Xiao-Jian Sun, Lan Wang
The bone marrow microenvironment (BMM) can regulate leukemia stem cells (LSC) via secreted factors. Increasing evidence suggests that dissecting the mechanisms by which BMM maintains LSC may lead to the development of effective therapies for the eradication of leukemia. Inhibitor of DNA binding 1 (ID1), a key transcriptional regulator in LSC previously identified by us, controls cytokine production in the BMM, but the role of ID1 in AML-BMM remains obscure. Here, we report that ID1 is highly expressed in the BMM of AML patients, especially in bone marrow mesenchymal stem cells (BMSCs), and the high expression of ID1 in AML-BMM is induced by BMP6, secreted from AML cells...
June 15, 2023: Blood